◆英語タイトル:Interprotein Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10865
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Interprotein Corp (Interprotein) is a drug development company that develops active modulators for protein-protein interaction (PPI) targets. The company offers products such as IL-6 inhibitor, IgE inhibitor, notch1 inhibitor, tubulin polymerization inhibitors, TIM-3 inhibitor, NKG2A, HLA-E and CD94 inhibitor, KIR and HLA-C inhibitor, gp130 inhibitor and RUNX1 and CBFß inhibitor. Its IL-6 inhibitor is used in the treatment of Castleman’s disease, rheumatoid arthritis and juvenile idiopathic arthritis, cachexia, and inflammatory and autoimmune diseases. The company operates through its laboratory located in Kanagawa, Japan. Interprotein is headquartered in Osaka City, Japan.
Interprotein Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Interprotein Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Interprotein Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Interprotein Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Interprotein Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Interprotein Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Interprotein Corp, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Interprotein Enters into R&D Agreement with A.I. Squared 10
Ipsen Enters into Research Agreement with Interprotein 11
Interprotein Enters Into Agreement With Takeda Pharma For PPI Inhibitors 12
RaQualia Pharma Enters Into Research Agreement With Interprotein For PPI Inhibitor 13
Interprotein Corp – Key Competitors 14
Interprotein Corp – Key Employees 15
Interprotein Corp – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Government and Public Interest 17
Feb 08, 2018: Interprotein: Program copyright registration of “the system for predicting pharmacological activity of compounds by AI (deep learning)” 17
Product News 18
May 16, 2018: AI-guided INTENDD, Interprotein’s AI drug discovery platform based on deep learning of binding structures of small molecules and target proteins, is transitioning into a practical stage 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19
List of Tables
Interprotein Corp, Pharmaceuticals & Healthcare, Key Facts 2
Interprotein Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Interprotein Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Interprotein Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Interprotein Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Interprotein Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Interprotein Enters into R&D Agreement with A.I. Squared 10
Ipsen Enters into Research Agreement with Interprotein 11
Interprotein Enters Into Agreement With Takeda Pharma For PPI Inhibitors 12
RaQualia Pharma Enters Into Research Agreement With Interprotein For PPI Inhibitor 13
Interprotein Corp, Key Competitors 14
Interprotein Corp, Key Employees 15
Interprotein Corp, Other Locations 16
List of Figures
Interprotein Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Interprotein Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Interprotein Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Interprotein Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Interprotein Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Interprotein Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Interprotein Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Interprotein Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8